Literature DB >> 23852705

A complete genomic analysis of hepatitis B virus isolated from 516 Chinese patients with different clinical manifestations.

Xiaodong Li1, Yan Liu, Zhihui Xu, Zhihong Wan, Siyu Bai, Panyong Mao, Yuanli Mao, Shaojie Xin, Dongping Xu.   

Abstract

This study investigated features and clinical implications of HBV mutations in patients with different clinical manifestations. In total, 516 patients were enrolled in this study, including 131 patients with acute hepatitis B, 239 patients with chronic hepatitis B, and 146 patients with acute-on-chronic liver failure. HBV genotypes and mutations were analyzed by direct sequencing of complete viral genomes. Genotypes B2, C1, C2, and D1 accounted for 22.2%, 1.6%, 74.6%, and 1.6%, respectively. Genotype B was more frequently detected in patients with acute hepatitis B than those with chronic hepatitis B and acute-on-chronic liver failure. Deletion mutations were detected mostly in preS1 and preS2 regions and the detection rates were 3.8%, 19.7%, and 24.7% for acute hepatitis B, chronic hepatitis B and acute-on-chronic liver failure patients, respectively. Incidences of point mutation T53C (preS1F53L), G1613A (polR841K), G1775A and A1762T + G1764A in the basal core promoter region, G1896A and G1899A in precore region and A2189C (coreI97L) in core region increased along with acute hepatitis B, chronic hepatitis B, and acute-on-chronic liver failure. The mutation G1896A was independently associated with poor survival of patients with acute-on-chronic liver failure. The gradual increase of viral mutation incidences was also observed in three HLA-A2-restricted cytotoxic T lymphocyte epitopes from HLA-A2-positive patients, that is env188-196 (5.8%, 10.1%, 22.5%), core107-115 (4.3%, 4.6%, 19.7%), and x92-100 (1.4%, 20.2%, 33.8%). In conclusion, certain viral mutations in various regions of HBV genome are associated with disease progression of HBV infection.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  disease progression; epitope; full-length genome; hepatitis B virus; mutation

Mesh:

Substances:

Year:  2013        PMID: 23852705     DOI: 10.1002/jmv.23640

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

Review 1.  Epidemiology of Hepatitis B Virus Infection in China: Current Status and Challenges.

Authors:  Yong-Ping Yan; Hai-Xia Su; Zhao-Hua Ji; Zhong-Jun Shao; Zhong-Shu Pu
Journal:  J Clin Transl Hepatol       Date:  2014-03-15

2.  Associations between hepatitis B virus basal core promoter/pre-core region mutations and the risk of acute-on-chronic liver failure: a meta-analysis.

Authors:  Feishu Hu; Sheng Bi; Huadong Yan; Yu Shi; Jifang Sheng
Journal:  Virol J       Date:  2015-06-11       Impact factor: 4.099

3.  Screening and Identification of HBV Epitopes Restricted by Multiple Prevalent HLA-A Allotypes.

Authors:  Yan Ding; Zining Zhou; Xingyu Li; Chen Zhao; Xiaoxiao Jin; Xiaotao Liu; Yandan Wu; Xueyin Mei; Jian Li; Jie Qiu; Chuanlai Shen
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

4.  Characterization of Novel Hepatitis B Virus PreS/S-Gene Mutations in a Patient with Occult Hepatitis B Virus Infection.

Authors:  Jianhong Chen; Yan Liu; Jun Zhao; Zhihui Xu; Rongjuan Chen; Lanlan Si; Shanshan Lu; Xiaodong Li; Shuai Wang; Kai Zhang; Jin Li; Juqiang Han; Dongping Xu
Journal:  PLoS One       Date:  2016-05-16       Impact factor: 3.240

5.  Effect of Tetanus-diphtheria Vaccine on Immune Response to Hepatitis B Vaccine in Low-responder Individuals.

Authors:  Abbas Haghighat; Mohammad Moafi; Jalil Sharifian; Hassan Salehi; Roya Taleban; Nader Kalbasi; Marzieh Salehi; Mohammad Mahdi Salehi; Maryam Salehi
Journal:  Int J Prev Med       Date:  2016-07-21

6.  Complete genome analysis of hepatitis B virus in Qinghai-Tibet plateau: the geographical distribution, genetic diversity, and co-existence of HBsAg and anti-HBs antibodies.

Authors:  He Liu; Liping Shen; Shuang Zhang; Feng Wang; Guomin Zhang; Zundong Yin; Feng Qiu; Xiaofeng Liang; Fuzhen Wang; Shengli Bi
Journal:  Virol J       Date:  2020-06-12       Impact factor: 4.099

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.